Literature DB >> 27870685

The Importance of Biopsy in the Era of Molecular Medicine.

Etay Ziv1, Jeremy C Durack, Stephen B Solomon.   

Abstract

Recent advances in the molecular characterization of cancers have triggered interest in developing a new taxonomy of disease in oncology with the goal of using the molecular profile of a patient's tumor to predict response to treatment. Image-guided needle biopsy is central to this "precision medicine" effort. In this review, we first discuss the current role of biopsy in relation to clinical examples of molecular medicine. We then outline important bottlenecks to the advancement of precision medicine and highlight the potential role of image-guided biopsy to address these challenges.

Entities:  

Mesh：

Year:  2016        PMID： 27870685      PMCID： PMC5588891          DOI： 10.1097/PPO.0000000000000228

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  57 in total

1.  Incorporating biomarkers into clinical trial designs: points to consider.

Authors:  Edward Bradley
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

2.  Effect of advanced imaging technology on how biopsies are done and who does them.

Authors:  Sharon W Kwan; Mythreyi Bhargavan; Robert K Kerlan; Jonathan H Sunshine
Journal:  Radiology       Date:  2010-06-29       Impact factor: 11.105

3.  Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2cm or smaller.

Authors:  Jun-ichi Nitadori; Adam J Bograd; Kyuichi Kadota; Camelia S Sima; Nabil P Rizk; Eduardo A Morales; Valerie W Rusch; William D Travis; Prasad S Adusumilli
Journal:  J Natl Cancer Inst       Date:  2013-08-07       Impact factor: 13.506

Review 4.  The changing face of percutaneous image-guided biopsy: molecular profiling and genomic analysis in current practice.

Authors:  Dustyn Marshall; Jeanne M Laberge; Brandie Firetag; Theodore Miller; Robert K Kerlan
Journal:  J Vasc Interv Radiol       Date:  2013-06-24       Impact factor: 3.464

5.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

6.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Authors:  Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn
Journal:  JAMA       Date:  2014-05-21       Impact factor: 56.272

7.  Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Authors:  Wendy De Roock; Bart Claes; David Bernasconi; Jef De Schutter; Bart Biesmans; George Fountzilas; Konstantine T Kalogeras; Vassiliki Kotoula; Demetris Papamichael; Pierre Laurent-Puig; Frédérique Penault-Llorca; Philippe Rougier; Bruno Vincenzi; Daniele Santini; Giuseppe Tonini; Federico Cappuzzo; Milo Frattini; Francesca Molinari; Piercarlo Saletti; Sara De Dosso; Miriam Martini; Alberto Bardelli; Salvatore Siena; Andrea Sartore-Bianchi; Josep Tabernero; Teresa Macarulla; Frédéric Di Fiore; Alice Oden Gangloff; Fortunato Ciardiello; Per Pfeiffer; Camilla Qvortrup; Tine Plato Hansen; Eric Van Cutsem; Hubert Piessevaux; Diether Lambrechts; Mauro Delorenzi; Sabine Tejpar
Journal:  Lancet Oncol       Date:  2010-07-08       Impact factor: 41.316

8.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

9.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

10.  Translation in solid cancer: are size-based response criteria an anachronism?

Authors:  M Fernandes; D Rosel; J Brábek
Journal:  Clin Transl Oncol       Date:  2014-07-30       Impact factor: 3.405
View more
  8 in total

1.  An interventional image-guided microdevice implantation and retrieval method for in-vivo drug response assessment.

Authors:  Sharath K Bhagavatula; Kunj Upadhyaya; Brendyn J Miller; Patrick Bursch; Alex Lammers; Michael J Cima; Stuart G Silverman; Oliver Jonas
Journal:  Med Phys       Date:  2019-09-26       Impact factor: 4.071

2.  Technical and nidus-specific factors associated with adequacy of intraprocedural biopsy samples preceding radiofrequency ablation of osteoid osteoma.

Authors:  Mohamed M Soliman; Allison Aguado; Charles Sutton; Meera Hameed; Sinchun Hwang; John H Healey; Majid Maybody
Journal:  Clin Imaging       Date:  2020-01-09       Impact factor: 1.605

Review 3.  The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.

Authors:  Virginia Liberini; Martin W Huellner; Serena Grimaldi; Monica Finessi; Philippe Thuillier; Alfredo Muni; Riccardo E Pellerito; Mauro G Papotti; Alessandro Piovesan; Emanuela Arvat; Désirée Deandreis
Journal:  Diagnostics (Basel)       Date:  2020-12-12

4.  The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers.

Authors:  Virginia Liberini; Riccardo Laudicella; Martina Capozza; Martin W Huellner; Irene A Burger; Sergio Baldari; Enzo Terreno; Désirée Deandreis
Journal:  Molecules       Date:  2021-04-11       Impact factor: 4.411

5.  Impact of segmentation and discretization on radiomic features in 68Ga-DOTA-TOC PET/CT images of neuroendocrine tumor.

Authors:  Virginia Liberini; Bruno De Santi; Osvaldo Rampado; Elena Gallio; Beatrice Dionisi; Francesco Ceci; Giulia Polverari; Philippe Thuillier; Filippo Molinari; Désirée Deandreis
Journal:  EJNMMI Phys       Date:  2021-02-27

6.  Surgical Treatment of Metastatic Bone Disease in the Appendicular Skeleton: A Population-Based Study.

Authors:  Thea Hovgaard Ladegaard; Celine Lykke Sørensen; Rasmus Nielsen; Anders Troelsen; Dhergam Ahmed Ali Al-Mousawi; Rikke Bielefeldt; Michael Mørk Petersen; Michala Skovlund Sørensen
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

7.  Integrated Workflow for the Label-Free Isolation and Genomic Analysis of Single Circulating Tumor Cells in Pancreatic Cancer.

Authors:  Brittany Rupp; Sarah Owen; Harrison Ball; Kaylee Judith Smith; Valerie Gunchick; Evan T Keller; Vaibhav Sahai; Sunitha Nagrath
Journal:  Int J Mol Sci       Date:  2022-07-16       Impact factor: 6.208

8.  Employing radiography (X-rays) to localize lesions in human skeletal remains from past populations to allow accurate biopsy, using examples of cancer metastases.

Authors:  Piers D Mitchell; Jenna M Dittmar
Journal:  Int J Osteoarchaeol       Date:  2022-01-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.